Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Selective oestrogen receptor antagonists inhibit oesophageal cancer cell proliferation in vitro

Authors: Waleed Al-Khyatt, Cristina Tufarelli, Raheela Khan, Syed Yousef Iftikhar

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Oestrogen receptors (ER) have a well-established role to the initiation, progression and regulation of responses to treatment of breast, prostate, and lung cancers. Previous data indicates altered ER expression in oesophageal cancers (OC). However the role of ER subtypes and ER specific inhibitors in the regulation of OC progression remains unclear. This study sought to assess levels of ERα and ERβ in OC. The effects of highly selective ER antagonists on cell proliferation and apoptosis in two OC adenocarcinoma cell lines was also studied.

Methods

ERα and ERβ expression profiling in paired normal oesophageal mucosa and tumour tissues (n = 34; adenocarcinoma n = 28; squamous cell carcinoma n = 6) was performed using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Correlation between levels of ER with the clinico-pathological features for OC was determined. The effect of selective ER antagonists on proliferation of OE33 and OE19 OC cell lines was studied.

Results

ERα and ERβ mRNA expression was significantly higher (p < 0.05) in tumour tissues relative to their paired normal mucosa and correlated inversely with survival outcome (p < 0.05). Upregulation of ERα mRNA correlated with higher pathological T-stage (p < 0.05) and lymph node metastasis (p < 0.05) while ERβ mRNA upregulation correlated with positive vascular invasion (p < 0.05). A significant concentration-dependent inhibition of proliferation in OE33 and OE19 cell lines was induced by a highly-selective ERα antagonist (MPP) and an ERβ specific antagonist (PHTPP) (p < 0.05). Moreover, anti-oestrogens induced cell death through stimulation of apoptotic caspase activity.

Conclusion

These findings indicate that the ER system is involved in OC progression and thus may provide a novel target for the treatment of OC.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Umar SB, Fleischer DE. Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol. 2008;5(9):517–26.CrossRef
4.
Naughton P, Walsh TN. Multimodality therapy for cancers of the esophagus and gastric cardia. Expert Rev Anticancer Ther. 2004;4(1):141–50.CrossRefPubMed
5.
Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63(4):232–48.CrossRefPubMed
6.
Mathieu LN, et al. Age and sex differences in the incidence of esophageal adenocarcinoma: results from the surveillance, epidemiology, and end results (SEER) registry (1973–2008). Dis Esophagus. 2013; p. n/a-n/a
7.
8.
Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184–7.CrossRefPubMedPubMedCentral
9.
Edgren G, et al. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187–96.CrossRefPubMed
10.
11.
12.
Rutegard M, et al. Oesophageal adenocarcinoma: the new epidemic in men? Maturitas. 2011;69(3):244–8.CrossRefPubMed
13.
Derakhshan MH, et al. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58(1):16–23.CrossRefPubMed
14.
Freedman ND, et al. The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. Cancer. 2010;116(6):1572–81.CrossRefPubMedPubMedCentral
15.
Bodelon C, et al. Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer Prev Res (Phila). 2011;4(6):840–50.CrossRef
16.
Green J, et al. Reproductive factors and risk of oesophageal and gastric cancer in the million women study cohort. Br J Cancer. 2012;106(1):210–6.CrossRefPubMed
17.
Morita M, et al. Gender differences in prognosis after esophagectomy for esophageal cancer. Surg Today. 2013:1–8.
18.
Nilsson S, Gustafsson JA. Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther. 2011;89(1):44–55.CrossRefPubMed
19.
Williams C, et al. Estrogen receptor beta as target for colorectal cancer prevention. Cancer Lett. 2016;372(1):48–56.CrossRefPubMed
20.
Li W, Tse LA, Wang F. Prognostic value of estrogen receptors mRNA expression in non-small cell lung cancer: a systematic review and meta-analysis. Steroids. 2015;104:129–36.CrossRefPubMed
21.
Luo Z, et al. Overexpression of estrogen receptor beta is a prognostic marker in non-small cell lung cancer: a meta-analysis. Int J Clin Exp Med. 2015;8(6):8686–97.PubMedPubMedCentral
22.
Walton TJ, et al. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate. 2008;68(2):210–22.CrossRefPubMed
23.
Jia M, Dahlman-Wright K, Gustafsson J-Å. Estrogen receptor alpha and beta in health and disease. Best Prac Res Clin Endocrinol Metabol. 2015;29(4):557–68.CrossRef
24.
Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11(8):597–608.CrossRefPubMed
25.
26.
27.
Kawashima H, Nakatani T. Involvement of estrogen receptors in prostatic diseases. Int J Urol. 2012;19(6):512–22. author reply 522-3CrossRefPubMed
28.
Kawai H, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res. 2005;11(14):5084–9.CrossRefPubMed
29.
Konstantinopoulos PA, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer. 2003;39(9):1251–8.CrossRefPubMed
30.
Jassam N, et al. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol Rep. 2005;14(1):17–21.PubMed
31.
Zuguchi M, et al. Estrogen receptor alpha and beta in esophageal squamous cell carcinoma. Cancer Sci. 2012;103(7):1348–55.CrossRefPubMed
32.
Sukocheva OA, et al. Effect of estrogen on growth and apoptosis in esophageal adenocarcinoma cells. Dis Esophagus. 2013;26(6):628–35.CrossRefPubMed
33.
Wang BJ, et al. Hormonal and reproductive factors and risk of esophageal cancer in women: a meta-analysis. Dis Esophagus. 2015; p. n/a-n/a
34.
Due SL, et al. Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells. Surg Oncol. 2016;25(3):269–77.CrossRefPubMed
35.
Bustin SA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–22.CrossRefPubMed
36.
McClelland RA, et al. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res. 1990;50(12):3545–50.PubMed
37.
38.
Giroux V, et al. Estrogen receptor β deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. Int J Cancer. 2008;123(2):303–11.CrossRefPubMed
39.
Martineti V, et al. ERβ is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Relat Cancer. 2005;12(2):455–69.CrossRefPubMed
40.
Wilkins H, et al. Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein, and decreasing transcription of the anti-apoptotic protein bcl-2. Tumor Biol. 2010;31(1):16–22.CrossRef
41.
Ström A, et al. Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A. 2004;101(6):1566–71.CrossRefPubMedPubMedCentral
42.
Lin C-Y, et al. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res. 2007;9(2):R25.CrossRefPubMedPubMedCentral
43.
Hartman J, Ström A, Gustafsson J-Å. Current concepts and significance of estrogen receptor β in prostate cancer. Steroids. 2012;77(12):1262–6.CrossRefPubMed
44.
Rades D, et al. The prognostic impact of tumor cell expression of estrogen receptor-alpha, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer. 2012;118(1):157–63.CrossRefPubMed
45.
Tiffin N, et al. Sex hormone receptor immunohistochemistry staining in Barrett's oesophagus and adenocarcinoma. Histopathology. 2003;42(1):95–6.CrossRefPubMed
46.
Nozoe T, et al. Significance of immunohistochemical expression of estrogen receptors alpha and beta in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2007;13(14):4046–50.CrossRefPubMed
47.
Akgun H, Lechago J, Younes M. Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus. Anticancer Res. 2002;22(3):1459–61.PubMed
48.
Liu L, Chirala M, Younes M. Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma. Anticancer Res. 2004;24(5A):2919–24.PubMed
49.
Kalayarasan R, et al. Estrogen and progesterone receptors in esophageal carcinoma. Dis Esophagus. 2008;21(4):298–303.CrossRefPubMed
50.
Driggers PH, Segars JH. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab. 2002;13(10):422–7.CrossRefPubMedPubMedCentral
51.
Katzenellenbogen BS, et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol. 2000;74(5):279–85.CrossRefPubMed
52.
53.
Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Asp Med. 2006;27(4):299–402.CrossRef
54.
Tyulmenkov VV, Klinge CM. Selectivity of antibodies to estrogen receptors alpha and beta (ERalpha and ERbeta) for detecting DNA-bound ERalpha and ERbeta in vitro. Steroids. 2000;65(9):505–12.CrossRefPubMed
55.
Pavao M, Traish AM. Estrogen receptor antibodies: specificity and utility in detection, localization and analyses of estrogen receptor alpha and beta. Steroids. 2001;66(1):1–16.CrossRefPubMed
56.
Robertson JF. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev. 2004;30(8):695–706.CrossRefPubMed
57.
Ung M, et al. Effect of estrogen receptor α binding on functional DNA methylation in breast cancer. Epigenetics. 2014;9(4):523–32.
Metadata
Title
Selective oestrogen receptor antagonists inhibit oesophageal cancer cell proliferation in vitro
Authors
Waleed Al-Khyatt
Cristina Tufarelli
Raheela Khan
Syed Yousef Iftikhar
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4030-5

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells

Research article

Women’s knowledge and attitudes related to cervical cancer and cervical cancer screening in Isiolo and Tharaka Nithi counties, Kenya: a cross-sectional study

Research article

Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean

Research article

Diet, obesity and colorectal carcinoma risk: results from a national cancer registry-based middle-eastern study

Research article

Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro

Study protocol

A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits